Protak Scientific is pleased to announce the release of Athena 2.0, our upgraded software for H202 bio-decontamination verification.
Athena is the Protak owned software that is used with Enzyme Indicators, an advanced validation tool for measuring decontamination performance instantly – already in use by companies such as Pfizer, Novo Nordisk, Roche and AstraZeneca.
Our Athena software validates and quantifies real-time results for cycle efficacy with FDA CFR part 21, part 11, compliance reporting. Athena 2.0 offers advanced reporting capability, enhanced audit and review features along with data archive facilities.
This innovative software development has been led by Protak’s talented Product Specialist team and supported by grant funding from our partnership with the Business Hothouse programme and Invest4, a HM Government backed match-fund. This funding has also supported our marketing and promotional activities following a challenging time during the Covid-19 pandemic.
Athena 2.0 – due for release 6 December, will enable us to continue our targeted market sector expansion and strategic growth.
